期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 32, 期 8, 页码 907-915出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2020.1720586
关键词
Psoriasis; Corrona Psoriasis Registry; effectiveness; ustekinumab
类别
资金
- Novartis Pharmaceuticals Corporation
- AbbVie
- Amgen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Crescendo
- Eli Lilly and Company
- Genentech
- Gilead
- GSK
- Janssen
- Merck
- Momenta Pharmaceuticals
- Novartis
- Pfizer Inc.
- Roche
- UCB
- Valeant
This study analyzed characteristics and outcomes of US patients with moderate-to-severe psoriasis who had insufficient responses to ustekinumab, finding a significant association between increasing age and decreased likelihood of achieving a response to the treatment.
Objective: Biologic therapies have revolutionized the management of moderate-to-severe psoriasis; however, there are a limited number of US real-world studies characterizing patients based on response to these treatments. This study examined characteristics at enrollment and change in outcomes of US patients with moderate-to-severe psoriasis who achieved insufficient responses with ustekinumab. Methods: This study included patients enrolled in the Corrona Psoriasis Registry from April 2015 to June 2018 who initiated ustekinumab at enrollment and who were stratified based on achievement of psoriasis body surface area improving to <3% or by 75% from enrollment to the 6-month follow-up visit (response vs insufficient response). Patient demographics and disease characteristics were described at enrollment, and changes in outcomes were assessed at 6-month follow-up for ustekinumab responders and insufficient responders. Results: Of the 178 patients who initiated ustekinumab in the Corrona Psoriasis Registry and had >= 1 follow-up visit, 99 (55.6%) were classified as responders at the 6-month follow-up visit. Logistic regression modeling showed that increasing age was significantly associated with a decreased likelihood of achieving a response (OR, 0.981 [95%CI, 0.962-0.999]; p = .049). Conclusions: These findings may help dermatologists characterize patients with moderate-to-severe psoriasis who have inadequate responses to biologic treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据